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Abstract
Background: To investigate glucose homeostasis in detail in Turner syndrome (TS), where impaired glucose
tolerance (IGT) and type 2 diabetes are frequent.
Methods: Cross sectional study of women with Turner syndrome (TS)(n = 13) and age and body mass index
matched controls (C) (n = 13), evaluated by glucose tolerance (oral and intravenous glucose tolerance test (OGTT
and IVGTT)), insulin sensitivity (hyperinsulinemic, euglycemic clamp), beta-cell function (hyperglycaemic clamp,
arginine and GLP-1 stimulation) and insulin pulsatility.
Results: Fasting glucose and insulin levels were similar. Higher glucose responses was seen in TS during OGTT and
IVGTT, persisting after correction for body weight or muscle mass, while insulin responses were similar in TS and C,
despite the higher glucose level in TS, leading to an insufficient increase in insulin response during dynamic
testing. Insulin sensitivity was comparable in the two groups (TS vs. control: 8.6 ± 1.8 vs. 8.9 ± 1.8 mg/kg*30 min;
p = 0.6), and the insulin responses to dynamic b-cell function tests were similar. Insulin secretion patterns examined by
deconvolution analysis, approximate entropy, spectral analysis and autocorrelation analysis were similar. In addition we
found low IGF-I, higher levels of cortisol and norepinephrine and an increased waist-hip ratio in TS.
Conclusions: Young normal weight TS women show significant glucose intolerance in spite of normal insulin
secretion during hyperglycaemic clamping and normal insulin sensitivity. We recommend regularly testing for
diabetes in TS.
Trial Registration: Registered with http://clinicaltrials.com, ID nr: NCT00419107
Background
Turner syndrome (TS) is usually associated with
reduced adult height and gonadal dysgenesis, premature
ovarian failure and infertility. Increased morbidity has
been reported with an increased risk of congenital and
acquired cardiovascular disease, thyroid disease, osteo-
porosis and diabetes. Early reports of impaired glucose
tolerance (IGT) in TS [1,2] have been followed by stu-
dies finding several abnormalities of the glucose metabo-
lism in both girls [3] and women [4,5] with TS.
Epidemiological studies have shown an increased risk of
developing both type 1 diabetes (relative risk: 11.6) and
type 2 diabetes (T2DM)(relative risk: 4.4) [6], in addition
to increased mortality due to diabetes [7,8].
IGT is present in 25-78% of adult TS populations
evaluated by oral glucose tolerance testing (OGTT)
[4,5], and seems to be more prevalent in TS compared
to both healthy controls and women with premature
ovarian failure and thus reduced oestrogen exposure [5].
Other studies have suggeste dt h ep r e s e n c eo fr e d u c e d
insulin sensitivity [3,9] or impaired beta-cell function
[4,5]. However, the exact mechanism behind the
increased occurrence of type 2 diabetes is not clear.
Our aim was to establish the separate roles of insulin
sensitivity and b-cell function on glucose homeostasis in
young women with TS compared to BMI and age matched
controls. We hypothesized that early b-cell failure would
be present and possibly aggravated by insulin resistance.
Methods
The study group consisted of 13 women with TS veri-
fied by karyotyping and 13 age- and BMI-matched con-
trol women. All TS but one had the karyotype 45, X,
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had earlier received growth hormone therapy. All parti-
cipants but one in the TS group completed all study
days.
The patients were recruited consecutively through the
National Society of Turner Contact Groups in Denmark.
All patients received hormone replacement therapy
(HRT).
Exclusion criteria were known diabetes, BMI above 30,
untreated hypo- or hyper-thyroidism, present or past
malignant disease, symptomatic heart disease or daily
use of prescribed medicine known to affect glucose
metabolism other than HRT. Control women did not
use any prescribed medicine including hormonal
contraception.
All participants received oral and written information
concerning the study prior to giving their written
informed consent. The protocol was carried out in
accordance with the Helsinki declaration and approved
by the Aarhus County Ethical Scientific Committee (no.
20040108).
Participants were examined over three days, day one
and two being consecutive days. The final examination
day was performed more than four weeks after day two.
Participants met in the morning after an overnight fast
from 10 pm the previous night on all three days, with-
out engaging in major physical exercise for 48 hours
before the investigations (Figure 1). The women were
examined independent of the period of their menstrual
cycle.
Body Composition
On day one, body weight, height, waist-to-hip ratio and
blood pressure was measured. Total and regional fat
mass (FM) (g), and lean body mass (LBM) (g) was mea-
sured by dual-energy X-ray absorptiometry (DXA) using
a Hologic QDR scanner (Hologic, Inc., Waltham Mass,
version 7.20D). Cross calibration was ensured through
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Figure 1 Study design of day 1, 2 and 3.O nd a y1a no r a lg l u c o s et o l e r a n c et e s t( O G T T ) ,a sw e l la sD E X As c a na n de x e r c i s et e s tw a s
performed. On day 2, we did the intravenous glucose tolerance test, followed by a hyperinsulinemic euglycemic clamp. Energy expenditure was
assessed in fasting condition and during the steady state period of the clamp. On day 3, we performed insulin pulsatility testing followed by a
graded hyperglycaemic clamp with arginine bolus and finally GLP-1 bolus to stress the b-cell maximally (for details - see Materials and Method
section).
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tom [10].
OGTT and Vo2max
An OGTT was performed, administering 75 g glucose
orally. Insulin, C-peptide, free fatty acids (FFA), trigly-
cerides, growth hormone (GH), IGF-I, glucagon-like
peptide 1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) were measured at baseline and at 15,
30, 45, 60, 90, 120 min. Serum insulin and plasma glu-
cose responses were measured as area under the curve
(AUC) and as the incremental AUC (iAUC) using the
trapezoidal rule.
A 6 min sub-maximal exercise test on a bicycle erg-
ometer (Monark Ergomertric 829 E, Monark, Varberg,
Sweden) was performed for estimation of Vo2max .
IVGTT and Indirect Calorimetry
On day two intravenous catheters (Venflon, Viggo AB,
Helsingborg; Sweden) was placed in an antecubal vein
for infusion and in an arterialized hand vein for blood
sampling. After 30 minutes bed-rest, baseline indirect
calorimetry was performed measuring resting energy
expenditure (EE) and respiratory quotient during
20 min (Deltatrac monitor, Datex Instrumentarium,
Helsinki, Finland) [11]. An IVGTT was performed and
g l u c o s e( 2 5ga s5 0 %g l u c o s e )w a sa d m i n i s t e r e da sa
bolus dose within 90 sec and subsequent blood samples
w e r ed r a w na t0 ,4 ,8 ,1 0 ,1 2 ,1 5 ,1 8 ,2 0 ,2 5 ,3 0 ,4 0 ,5 0
and 60 min.
Hyperinsulinemic Euglycemic Clamp
The IVGTT was followed by a hyperinsulinemic eugly-
cemic clamp as previously described [12]. At 60 min
infusion of 1.0 mU/kg/min insulin was initiated and
infusion of 20% glucose was adjusted to stabilize
plasma glucose around 5.0 mmol/l. Minutes 150-180
were considered as a hyperinsulinemic steady state and
during this period the indirect calorimetric measure-
ment was repeated and samples of blood were drawn
every 15 min.
Insulin Pulsatility
Initially on study day three spontaneous insulin secre-
tion was recorded by measuring insulin levels every
minute for 60 minutes. Serum insulin concentration
time series were evaluated by deconvolution analysis,
autocorrelation analysis, spectral analysis and approxi-
mate entropy.
Deconvolution analysis
Serum insulin concentration time series were analyzed
in a blinded manner by deconvolution analysis to quan-
titate insulin secretory burst mass, burst amplitude,
basal secretion, and interpulse interval [13,14].
Detrending
To eliminate the effects of nonstationarity in the data,
approximate entropy (ApEn), spectral analysis, and auto-
correlation analysis were performed on the residuals,
after subtraction of an 11-point centered moving aver-
age process [15]. This length of the moving average pro-
cess was chosen to ensure optimal detrending.
ApEn
ApEn measures the likelihood that patterns repeat
throughout the time series [15]. By application of a
small r value (e.g. r = 0.2 sd), ApEn evaluates fine (sub)
patterns in the time series, and a larger r value (e.g.r=
1 . 0s d )i sa p p l i e dt oe v a l u a t em o r ec o a r s ep a t t e r n s .
A higher ApEn value indicates a more irregular time
series.
Spectral analysis and autocorrelation analysis
By spectral analysis insulin concentration time series is
described by sinus waves of different frequencies. The
predominant frequency and the density hereof was
recorded. A Tukey window of 25 data points was used,
and spectra were normalized, assuming that the total
variance in each time series was 100%, enabling compar-
ison of spectral estimates despite the different absolute
insulin values. Autocorrelation analysis was performed
and the lag time and the maximal autocorrelation coeffi-
cient were recorded. All data analyses were performed
in a blinded manner.
Graded Hyperglycemic Clamp, Arginine and GLP-1 bolus
Following insulin pulsatility testing, a graded hyperglyce-
mic clamp was applied on day three. At 60 minutes glu-
cose levels were raised to 7 mmol/l by the use of
b e t w e e n2a n d5m l5 0 %g l u c o s ea n dc o n t i n u o u si n f u -
sion of 20% glucose, to raise glucose as quickly as possi-
ble and clamp glucose at levels 7, 9, 10, 11 and
12 mmol/l for 30-minute intervals. After 30 min at glu-
c o s el e v e lo f1 2m m o l / la5gi . v . - b o l u so fa r g i n i n ew a s
administered measuring the effect on baseline para-
meters every 5 minutes for 30 minutes. This was fol-
lowed by an iv-bolus of 2.5 nmol GLP-1 and the effect
was likewise monitored for 30 min.
Assays
Plasma glucose was measured in duplicate immediately
after sampling on a Beckman Glucoanalyzer (Beckman
Instruments, Palo Alto, CA, USA). Serum insulin was
measured by ELISA employing a two-site immunoassay
(DakoCytomation, Cambridgeshire, United Kingdom),
C-peptide by ELISA (DakoCytomation, Cambridgeshire,
United Kingdom), serum FFA by a colorimetric method
(Wako Pure Chemical Industries, Neuss, Germany),
plasma TG by COBAS Fara II, serum GH and cortisol
by time-resolved flouroimmunoassay (AutoDELFIA, Per-
kinElmer, Wallac, Turku, Finland). Total IGF-I was
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norepinephrine were measured by HPLC [17], glucagon
by an in-house radioimmunoassay, GLP-1 by a C-
terminal radioimmunoassay [18] and total GIP as pre-
viously described [19].
Statistical methods
The number of participants was determined from a
power calculation based on a minimal difference in glu-
cose levels (area under the curve (AUC)) during an
OGTT of 4.4 mmol/L/2 hours in women with TS and
controls and estimating an a of 0.05 and a power of
80% [4], which lead to a minimum sample size of 12.
Using data on insulin sensitivity in TS estimated by a
euglycemic hyperinsulinemic clamp [9], would have
yielded a minimal sample size of 8.3. All statistical cal-
culations were done using SPSS 15.0. Insulin and glu-
cose response to varying stimuli were compared by area
under the curve (AUC) computation. Results are
expressed as mean ± standard deviation (SD). For inter
group comparison a paired test was applied since TS
and controls were closely matched individually on age
and BMI. P-values less than 5% were considered
significant.
Results
Anthropometry and energy expenditure
The close matching of TS and controls resulted in com-
p a r a b l ea g e ,B M I ,F M( % )a n dL B M( % )( T a b l e1 ) .
Waist-hip ratio and maximal oxygen uptake were higher
in TS (Table 1).
Energy expenditure (EE) was similar in TS and con-
trols in both basal state and during the clamp steady
state (data not shown). No difference was found in EE
change (ΔEE) (ΔEE 103.8 ± 74.2 vs. 123.1 ± 46.3; p =
0.5). No significant difference in respiratory quotient
(RQ) was present between groups, in neither basal nor
steady state conditions (basal: p = 0.3; steady state:
p = 0.4).
OGTT
Fasting levels and 2 hour levels of glucose and insulin
were similar in TS and controls (fasting glucose: p = 0.4;
2hg l u c o s e :p=0 . 0 6 ;f a s t i n gi n s u l i n :p=0 . 3 ;2hi n s u -
lin: p = 0.2), while AUCglucose was higher in women
with TS, but AUCinsulin was comparable, indicating a
relatively lower insulin response in TS (Figure 2) and
correcting for total bodyweight or LBM did not change
this (results not shown). IGT (2 h glucose > 7.6 mmol/l)
was present in two women with TS and no controls.
The ratio AUCinsulin /AUCglucose was almost significantly
different between groups (TS vs. control: 28.7 ± 6.1 vs.
36.8 ± 10.8; p = 0.054). Results from analysis of C-
peptide data were similar to insulin results (p = 0.08).
Exclusion of the 2 TS subjects with IGT and their con-
trols did not change these findings.
Triglycerides levels were significantly lower among TS
(AUCtrigly: 85.4 ± 22.1 vs. 118.7 ± 42.5 mmol/L*2 h; p =
0.004) (Figure 2). Likewise IGF-I was lower in TS
(AUCIGF-1: 24970 ± 5792 vs. 33023 ± 7619 μg/L*2 h;
p = 0.004), a difference already present at baseline (IGF-
1t=0 : 201 ± 49 vs. 252 ± 91 μg/L; p < 0.001). No signif-
icant difference was found in FFA, GLP-1, GIP or GH
levels during the OGTT (Figure 2).
IVGTT
The 60 minutes glucose response to intravenous glucose
(25 g) was higher in TS vs. controls (p < 0.001), even
after correction for bodyweight (BW) (AUCglucose corBW:
11.8 ± 2.4 vs. 7.7 ± 1.5 mmol/l*60 min*kg; p < 0.001),
suggesting a reduced ability to respond to a glucose
load. Both first phase insulin response (AUC0-10 min,
2940 ± 1355 vs. 2703 ± 922 pmol/l*10 min, p = 0.6) and
the 60 minutes insulin response were similar in the
groups (AUC0-10 min, 10289 ± 4589 vs. 8343 ± 1950
pmol/l*60 min, p = 0.2), despite higher glucose levels
among TS. When corrected for bodyweight there was,
however, a higher insulin response (0-60 min) in TS
compared to controls (AUCinsulincorBW: 190 ± 90 vs.
121 ± 27 pmol/l*60 min*kg; p = 0.03), as would be
expected due to the higher glucose levels in TS. This
finding did not persist if the two women with TS and
IGT and their corresponding controls were excluded.
The weight adjusted first phase insulin response (0-
10 min) was, however, still similar in the two groups
Table 1 Anthopometric and clinical data on study
participants
TS (N = 13) Control (N = 13)
Age (years) 33.2 ± 4.8 33.7 ± 5.5 NS
Height (cm) 150.1 ± 6.8 168.3 ± 6 < 0.01
Weight (kg) 55.5 ± 8 69.6 ± 10.5 < 0.01
BMI (kg/m
2) 24.6 ± 3 24.5 ± 3.1 NS
Waist (cm) 78.3 ± 7.7 78.1 ± 8.4 NS
Hip (cm) 94.5 ± 7 105.9 ± 7.8 <0.01
Waist-hip ratio 0.83 ± 0.06 0.74 ± 0.06 <0.01
Systolic blood
pressure (mmHg)
115.1 ± 11.4 116.5 ± 9.2 NS
Diastolic blood
pressure (mmHg)
73.6 ± 12.4 70.4 ± 9.2 NS
Vo2max (mlO2/kg) 45.2 ± 7.2 37.6 ± 8.2 <0.004
FM (kg) 17.7 ± 4.6 21.5 ± 6.6 0.02
FM (%) 32.3 ± 5.8 31.2 ± 5.6 NS
LBM (kg) 34.6 ± 4.5 44 ± 5.2 <0.01
LBM (%) 64.4 ± 5.4 65.3 ± 5.2 NS
Antroprometric data, blood pressure and bocycomposition data from TS
women and controls. Values are mean ± SD. Fat mass (FM) and lean body
mass (LBM) are shown as total (kg) and percentage (%).
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Figure 2 Levels of glucose, insulin, glucagon-like. peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP); free fatty acids
(FFA), triglycerides, Insulin-like growth factor 1(IGF-1) and growth hormone (GH) during the 2-hour oral glucose tolerance test. P-values are
based on differences between TS and controls based on AUC and given in the figure. All mean ± SD.
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Page 5 of 10(AUCinsulincorBW: 53 ± 24 vs. 39 ± 12 pmol/l*10 min*kg;
p = 0.07). Calculation of a glucose/insulin ratio revealed
no difference between groups (ratio AUCinsulin/AUCglu-
cose: 16.5 ± 8.1; 16.0 ± 3.6; p = 0.9). No difference was
found in FFA levels at baseline or during the IVGTT
(baseline: p = 0.5; AUCFFA: p = 0.4).
Hyperinsulinemic euglycemic clamp
The insulin stimulated glucose uptake (M-value)
obtained from the hyperinsulinemic, euglycemic clamp
(8.6 ± 1.8 vs. 8.9 ± 1.8 mg/kg*30 min; p = 0.6) and
uptake per LBM (13.7 ± 2.7 vs. 14.0 ± 2.2 mg/kg
LBM*30 min; p = 0.7) were similar in the two study
groups. The insulin levels during the last 30 minutes of
the clamp, were slightly higher in controls (338 ± 56 vs.
380 ± 45 nmol/l; p = 0.04). The disposition index calcu-
lated using iAUC and the M-value was not significantly
different between groups (p = 0.4).
Cortisol levels were elevated in TS both at baseline
(365 ± 162 vs. 243 ± 112 nmol/l; p = 0.04) and during the
steady state of the hyperinsulinemic clamp (AUCcortisol:
7828 ± 3699 vs. 5128 ± 2046 nmol/l*30 min; p = 0.03), as
was steady state norepinephrine (AUCnorepinephrine:
7421 ± 1769 vs. 6037 ± 1802 pg/ml*30 min; p = 0.04).
Levels of glucagon (AUCGlucagon: 599 ± 519 vs. 584 ± 179
pg/ml*30 min, p = 0.9), GH (AUCGH:2 6±3 8v s .6 9±
113 ng/ml*30 min, p = 0.2) and epinephrine (AUCepi:
1533 ± 2054 vs. 1269 ± 457 pg/ml*30 min, p = 0.7) were
similar during the steady state period of the clamp.
Insulin Pulsatility
The overall insulin release was comparable between TS
and control women, with similar burst mass and ampli-
tude, as well as basal secretion. The regularity of the
insulin release pattern, as assessed by approximate
entropy was similar, as was the spectral power and the
autocorrelation coefficient (Table 2).
Graded hyperglycaemic clamp, arginine and GLP-1 bolus
Beta-cell function was measured as the insulin response
to hyperglycaemia, arginine and GLP-1 stimulation.
During the entire stimulation period the levels of glu-
cose and insulin were identical in the groups (Figure 3).
No significant difference in FFA or GH levels was pre-
sent during the hyperglycaemic clamp, and glucagon
levels during arginine and GLP-1 stimulation were simi-
lar between groups (Figure 4). GLP-1 was measured to
verify a sufficient response to the bolus injection.
Discussion
The salient results of the present study are the discrete
perturbations in the glucose handling in young females
with Turner syndrome. We found an increased level of
glucose during 1) the OGTT and 2) during the IVGTT,
and an insufficient concomitant compensatory increase
in the level of insulin, resulting in a reduced insulin-to-
glucose ratio. The study provides a detailed assessment
of the glucose homeostasis in TS, and it extends and
refines the results of previous studies. Study participants
in the present study were matched closely, not only on
age and BMI, but also on body fat. Using the gold stan-
dard for determining insulin sensitivity, the euglycemic
clamp, we found no difference between TS and controls.
The backdrop for the present study is epidemiological
data showing a four-fold increase in the risk of T2DM
[6]. Similar fasting glucose and insulin levels are present
in TS and controls [4,20,5,21]. Previous studies of insu-
lin sensitivity in TS have shown equivocal results, in
Table 2 Insulin pulsatility analysis
TS (N = 12) Control (N = 13)
Mean ± SD Range Mean ± SD Range P-value
Deconvolution
Mass (pmol/L/pulse) 12.14 ± 3.93 7 - 17.5 15.49 ± 8.1 8 - 38.2 0.2
Amplitude (pmol/L*min) 9.67 ± 3.15 5.5 - 13.9 12.35 ± 6.46 6.4 - 30.5 0.2
Pulse interval (min/pulse) 7.92 ± 1.71 6.1 - 12.4 7.49 ± 0.95 6 - 9.5 0.3
Basal secretion (pmol/L*min) 4.63 ± 2.25 4.48 - 2.09 4.48 ± 2.09 1.7 - 7.3 0.7
Pulse fraction 0.28 ± 0.11 0.33 ± 0.11 0.1
Regularity Analysis
ApEn (m = 1, r = 0.2 × SD) 1.34 ± 0.15 0.974 - 1.503 1.39 ± 0.058 1.32 - 1.51 0.3
ApEn (m = 1, r = 1.0 × SD) 0.586 ± 0.19 0.035 - 0.772 0.637 ± 0.073 0.5 - 0.762 0.4
Spectral power 7.03 ± 2.85 3.3 - 11.9 7.58 ± 2.2 4.3 - 12.8 0.4
Spectral frequency 10.58 ± 2.27 8 - 13 10.69 ± 2.39 7 - 13 0.6
Autocorrelation coefficient 0.198 ± 0.144 0.005 - 0.462 0.246 ± 0.129 0.05 - 0.468 0.3
Autocorrelation frequency 9.0 ± 2.8 6 - 15 9.62 ± 2.29 6 - 13 0.05
Parameters of pulsatility analysis based on deconvolution analysis, spectral analysis, and autocorrelation analysis and on the estimation of approximate entropy
(ApEn) of individual insulin concentration time series in TS and controls.
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Reduced insulin sensitivity among children [3,22] and
adults [9] has been reported, but here TS had signifi-
cantly higher BMI compared to controls. Studies of BMI
and fat mass matched groups of TS and controls have
not found insulin resistance to be an important trait in
TS [4,5,21]. Deficits in glucose metabolism seem to be
present after glucose stimulation, and it has repeatedly
been demonstrated that the response to oral glucose sti-
mulation is impaired in TS [4,5,23]. In the present study
2 (18%) participants with TS had IGT, none in the con-
trol group. Impaired glucose tolerance was not an exclu-
sion criterion in this study, which can be disputed, but
this would exclude up to 50% of the TS population,
resulting in a group of TS which would not be represen-
tative for the population. Leaving the two TS with IGT
out of the data analysis, however, only changed the
results marginally in regard to the OGTT, but not in
regard to the results from the IVGTT.
To our knowledge b-cell function in this patient group
has not been studied thoroughly before. The b-cell func-
tion in theory depends on: 1) the total b-cell mass,
2) the sensitivity of the individual cells to the stimulus
and 3) the secretory capacity of the individual cell [24].
Intravenously administered hyperglycaemia, followed by
first arginine, then GLP-1, resulted in an insulin
response of the same magnitude in TS and controls.
However, the first phase insulin response (0-10 min)
during the IVGTT demonstrates a reduced insulin peak
relative to the glucose peak in TS. This could suggest
that the discrete reduction in insulin secretion following
a glucose load is time dependant and becomes apparent
a f t e ra na c u t eg l u c o s el o a d ,d u et oad e l a yi ni n s u l i n
secretion. This has earlier been described in a small TS
population tested by OGTT [25], as also shown here
with an increased AUC of glucose but comparable AUC
for insulin compared with controls during the OGTT.
By closely matching on age and BMI we have eliminated
some of the confounding factors of IGT not directly
linked to TS. Recently, Bakalov et al found a 25% preva-
lence of T2DM among a large group of adult TS tested
by OGTT (n = 224) with a mean age of 35 years [23],
corroborating epidemiological evidence [6-8]. They went
on to divide their study group by karyotype into patients
with delXq with a T2DM rate of 9% (similar to the
T2DM rate in the background population), 45, X with a
rate of 18%, delXp with a rate of 23%, and impressively,
a rate of 43% among subjects with isochromosome Xq.
These data suggests that haploinsufficiency of genes on
Xp increases the risk of T2DM to 18-23%, and addition-
ally that haploinsufficiency of Xp combined with trisomy
for Xq genes (karyotypes with isochromosome Xq)
further increases the risk of T2DM [23]. Gene expres-
sion profiling of 45, X and isochromosome Xq groups
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Page 7 of 10suggested overexpression of transcription factors
involved in diabetes, pancreatic islet and b-cell function,
as well as proinflammatory action in patients with iso-
chromosome Xq and mirrored by increased levels of cir-
culating CRP, IGF2 and GAD antibodies. Increased CRP
[26,21]and GAD antibodies has been found before and
the latter has been linked to the presence of isochromo-
some Xq [27]. Likewise, it is well known that the rate of
autoimmunity in general is hugely increased in TS [28]
being most pronounced for females with isochromo-
some Xq [28], and possibly also affected by the presence
of allelic variation of the other genes on other chromo-
somes, such as PTPN22 gene [29].
D u r i n gt h eI V G T Tas t a n d a r dd o s eo fg l u c o s ew a s
given, which means that participants with TS and a
smaller body size received a relatively higher dose of
glucose compared to controls. However, one would have
expected a similar glucose level, with an appropriately
increased level of insulin among TS. The present and
previous results point towards a relative inability of
patients with TS to respond appropriately to a glucose
load, however not dependent on the prevailing estradiol
level, since the defect in glucose handling is present
both during basal circumstances and during hormone
substitution therapy [4].
During the OGTT triglycerides were lower among TS,
as was serum IGF-I, as also seen in previous studies
where we found evidence of perturbation of the entire
GH-IGF-IGFBP axis [30-32]. Interestingly, a recent
study in children with TS showed that previously GH
treated girls had less subcutaneous and visceral fat and
less glucose intolerance than GH naïve girls, pointing
towards either a long lasting protective effect of GH
treatment on body composition and glucose homeostasis
or that GH treatment actually corrected some underly-
ing GH deficiency or a combination of both [33].
In addition we found higher levels of cortisol and nor-
epinephrine during the euglycemic clamp. The elevation
of cortisol may well be due to HRT induced elevation of
cortisol binding globulin, which leads to elevated total
cortisol (measured here), but does not increase free cor-
tisol [34]. Elevated norepinephrine leves has been
described before and linked to dysregulation of sympa-
thetic nervous system and resting tachycardia [35].
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Page 8 of 10Taken together, these data from the OGTT, IVGTT and
clamp studies, suggests that a number of variables, such
as prevailing levels of IGF-I (and indeed the entire GH-
IGF-IGFBP axis [32]), norepinephrine and triglycerides,
and possibly concepts such as glucose toxicity and lipo-
toxicity, might interact, influence and perhaps explain
the perturbed b-cell function seen in this and other stu-
dies. Recent data suggests that interesting genes will be
discovered in the future; both on Xp and Xq [23], and
that expression of these genes will provide new targets
for treatment of T2DM, both in TS, but certainly also in
a broader T2DM population.
Unexpectedly, and contrary to earlier findings, we
found a higher VO2max in our patient population
[31,4,36]. Still, it seems unlikely that this alone could
explain the present differences in glucose metabolism.
In addition, the dynamics of high-frequency insulin
oscillations were normal as assessed by analysis of min-
ute-to-minute insulin measurements, pointing towards a
normal baseline b-cell function. This method has pre-
viously been demonstrated to be a sensitive marker of
b-cell function [37].
Conclusions
Thus, the presented data show that neither decreased
insulin sensitivity nor significantly decreased b-cell func-
tion after stimulation with hyperglycaemia or during
challenge with arginine and GLP-1 explain the abnorm-
alities in the glucose homeostasis in TS. However,
young women with TS show early discrete signs of
decreased b-cell function during testing with OGTT and
IVGTT, and the data could be interpreted as a syn-
drome specific background for the development of dia-
betes [23], with involvement of multiple variables, such
as IGF-I, norepinephrine and triglycerides. We recom-
mend that all women with TS are tested regularly for
the presence of diabetes, and we suggest that the high
rate of T2DM is due to faltering b-cell function as pre-
sented here has a genetic basis.
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